Get the Stockscreener App
12.60
2.02%
-0.26
Mineralys Therapeutics Inc stock is traded at $12.60, with a volume of 183.67K.
It is down -2.02% in the last 24 hours and down -12.50% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
See More
Previous Close:
$12.86
Open:
$12.93
24h Volume:
183.67K
Relative Volume:
1.12
Market Cap:
$627.09M
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-8.933
EPS:
-1.4105
Net Cash Flow:
$-97.30M
1W Performance:
+1.20%
1M Performance:
-12.50%
6M Performance:
-1.64%
1Y Performance:
+95.96%
1-Day Range:
$12.23
$13.05
1-Week Range:
$11.30
$13.05
52-Week Range:
$5.85
$16.91
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MLYS | 12.60 | 627.09M | 0 | -119.67M | -97.30M | -1.4105 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN
Mineralys Therapeutics to Participate in Goldman Sachs Healthcare Conference - MSN
Mineralys Therapeutics Set to Engage with Investors at Key Conferences - MSN
Mineralys Therapeutics Inc (MLYS) Quarterly 10-Q Report - Quartzy
What is Lifesci Capital's Forecast for MLYS FY2024 Earnings? - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for MLYS - MarketBeat
(MLYS) Trading Signals - Stock Traders Daily
Mineralys therapeutics CMO sells shares worth $75,398 By Investing.com - Investing.com Australia
MineralysTargeting Aldosterone To Combat Obesity-Driven Hypertension And Kidney Disease - RTTNews
Mineralys Therapeutics Announces Q3 2024 Results and Updates - Yahoo Finance
Mineralys Therapeutics' (MLYS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Call Transcript - MSN
Mineralys Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mineralys Therapeutics reports Q3 EPS ($1.13), consensus (83c) - TipRanks
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
David Malcom Rodman Sells 25,482 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics' chief medical officer sells $383,065 in stock - Investing.com
Mineralys Therapeutics to Announce Third-Quarter 2024 Financial Results - MyChesCo
Mineralys Therapeutics (MLYS) to Release Quarterly Earnings on Monday - MarketBeat
Mineralys Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Mineralys Therapeutics (MLYS) to Present at Three Major Healthcare Conferences | MLYS Stock News - StockTitan
Mineralys Therapeutics to Announce Third Quarter 2024 - GlobeNewswire
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Marketscreener.com
Mineralys Therapeutics’ (MLYS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Objective long/short (MLYS) Report - Stock Traders Daily
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial - MSN
Mineralys Therapeutics (NASDAQ:MLYS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Mineralys Therapeutics : Corporate Overview October 2024 - Marketscreener.com
Mineralys Therapeutics Advances Lorundrostat Trial Progress - TipRanks
Mineralys Therapeutics Completes Enrollment Ahead of - GlobeNewswire
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - The Manila Times
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN
Context Therapeutics to Engage Investors at November Conferences - MyChesCo
Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances - MyChesCo
When the Price of (MLYS) Talks, People Listen - Stock Traders Daily
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - The Manila Times
Mineralys to Host Virtual KOL Event on the Unmet Medical - GlobeNewswire
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance
Hypertension Clinical Trials 2024: FDA Approvals, Medication, - openPR
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
Mineralys Therapeutics CEO sells $206,433 in stock - Investing.com
Mineralys Therapeutics CEO sells $206,433 in stock By Investing.com - Investing.com Canada
Mineralys therapeutics CFO Adam Levy sells $146,003 in stock By Investing.com - Investing.com South Africa
Mineralys therapeutics CFO Adam Levy sells $146,003 in stock - Investing.com
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,271 Shares - GuruFocus.com
Insider Sale: CFO Adam Levy Sells Shares of Mineralys Therapeuti - GuruFocus.com
Adam Scott Levy Sells 10,757 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):